Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk

Vinicius Tragante, Folkert W Asselbergs, Daniel I Swerdlow, Tom M Palmer, Jason H Moore, Paul I W de Bakker, Brendan J Keating, Michael V Holmes, Vinicius Tragante, Folkert W Asselbergs, Daniel I Swerdlow, Tom M Palmer, Jason H Moore, Paul I W de Bakker, Brendan J Keating, Michael V Holmes

Abstract

Therapeutic interventions that lower LDL-cholesterol effectively reduce the risk of coronary artery disease (CAD). However, statins, the most widely prescribed LDL-cholesterol lowering drugs, increase diabetes risk. We used genome-wide association study (GWAS) data in the public domain to investigate the relationship of LDL-C and diabetes and identify loci encoding potential drug targets for LDL-cholesterol modification without causing dysglycemia. We obtained summary-level GWAS data for LDL-C from GLGC, glycemic traits from MAGIC, diabetes from DIAGRAM and CAD from CARDIoGRAMplusC4D consortia. Mendelian randomization analyses identified a one standard deviation (SD) increase in LDL-C caused an increased risk of CAD (odds ratio [OR] 1.63 (95 % confidence interval [CI] 1.55, 1.71), which was not influenced by removing SNPs associated with diabetes. LDL-C/CAD-associated SNPs showed consistent effect directions (binomial P = 6.85 × 10(-5)). Conversely, a 1-SD increase in LDL-C was causally protective of diabetes (OR 0.86; 95 % CI 0.81, 0.91), however LDL-cholesterol/diabetes-associated SNPs did not show consistent effect directions (binomial P = 0.15). HMGCR, our positive control, associated with LDL-C, CAD and a glycemic composite (derived from GWAS meta-analysis of four glycemic traits and diabetes). In contrast, PCSK9, APOB, LPA, CETP, PLG, NPC1L1 and ALDH2 were identified as "druggable" loci that alter LDL-C and risk of CAD without displaying associations with dysglycemia. In conclusion, LDL-C increases the risk of CAD and the relationship is independent of any association of LDL-C with diabetes. Loci that encode targets of emerging LDL-C lowering drugs do not associate with dysglycemia, and this provides provisional evidence that new LDL-C lowering drugs (such as PCSK9 inhibitors) may not influence risk of diabetes.

Trial registration: ClinicalTrials.gov NCT01475825 NCT02160899.

Conflict of interest statement

DIS is a consultant to Pfizer.

Figures

Fig. 1
Fig. 1
Relationship of LDL-C-associated loci with risk of CAD. The majority (22 of 25) of loci showed a consistent direction of effect with risk of CAD. LDL-C effect estimates are per SD; whiskers represent 95 % CI
Fig. 2
Fig. 2
Mendelian randomization to investigate the causal relationship of a one standard deviation genetically-instrumented increase in LDL-C with risk of coronary artery disease (CAD), type 2 diabetes (T2D) and levels of fasting glucose. Single nucleotide polymorphisms (SNPs) were initially selected based on their independent association with LDL-C at R2 < 0.8 (n = 197; “All SNPs” stratum). Thereafter, we removed SNPs that associated with T2D risk at P < 0.01 (15 SNPs removed) and P < 0.05 (34 SNPs removed). Findings for the analysis using a stricter R2 threshold (<0.2) are presented in Supplementary Figure 4
Fig. 3
Fig. 3
Relationship of LDL-C-associated loci with risk of T2D. Six of the 15 loci showed a positive association with T2D risk. LDL-C effect estimates are per SD; whiskers represent 95 % CI
Fig. 4
Fig. 4
Relationship of LDL-C-associated loci with fasting glucose. Nine of 19 loci showed a positive association with fasting glucose. LDL-C effect estimates are per SD; Fasting glucose effect estimates are in mmol/l; whiskers represent 95 % CI
Fig. 5
Fig. 5
Circos diagram to show association of SNPs in PCSK9, APOB, LPA, LDLR and HMGCR with glycemic burden composite. The outer ring represents the genomic/chromosomal location. Each SNP is a green, orange or red point in the graph. Green dots in green shaded ring represent SNPs with 1 > P ≥ 0.05; orange circles in orange shaded ring correspond to SNPs within 0.05 > P ≥ 0.001 and; red triangles in red shaded ring represent SNPs with P < 0.001. 61 % of HMGCR SNPs associated with the glycemic burden composite (at P < 0.05) vs. less than 5 % for SNPs in PCSK9, APOB and LPA (color figure online)

References

    1. Akdim F, Stroes ES, Sijbrands EJ, Tribble DL, Trip MD, Jukema JW, Flaim JD, Su J, Yu R, Baker BF, Wedel MK, Kastelein JJ. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol. 2010;55:1611–1618. doi: 10.1016/j.jacc.2009.11.069.
    1. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ. 1998;316:1337–1343. doi: 10.1136/bmj.316.7141.1337.
    1. Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW, 3rd, Sisk CM, Mitchel Y, Pasternak RC. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157(352–360):e2.
    1. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44:512–525. doi: 10.1093/ije/dyv080.
    1. Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol. 2015;15(181):251–260. doi: 10.1093/aje/kwu283.
    1. Cannon Christopher P., Blazing Michael A., Giugliano Robert P., McCagg Amy, White Jennifer A., Theroux Pierre, Darius Harald, Lewis Basil S., Ophuis Ton Oude, Jukema J. Wouter, De Ferrari Gaetano M., Ruzyllo Witold, De Lucca Paul, Im KyungAh, Bohula Erin A., Reist Craig, Wiviott Stephen D., Tershakovec Andrew M., Musliner Thomas A., Braunwald Eugene, Califf Robert M. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine. 2015;372(25):2387–2397. doi: 10.1056/NEJMoa1410489.
    1. Chen L, Pawlikowski B, Schlessinger A, More SS, Stryke D, Johns SJ, Portman MA, Chen E, Ferrin TE, Sali A, Giacomini KM. Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet Genomics. 2010;20:687–699. doi: 10.1097/FPC.0b013e32833fe789.
    1. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. doi: 10.1016/S0140-6736(10)61350-5.
    1. Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–590. doi: 10.1016/S0140-6736(12)60367-5.
    1. Deloukas Panos, Kanoni Stavroula, Willenborg Christina, Farrall Martin, Assimes Themistocles L, Thompson John R, Ingelsson Erik, Saleheen Danish, Erdmann Jeanette, Goldstein Benjamin A, Stirrups Kathleen, König Inke R, Cazier Jean-Baptiste, Johansson Åsa, Hall Alistair S, Lee Jong-Young, Willer Cristen J, Chambers John C, Esko Tõnu, Folkersen Lasse, Goel Anuj, Grundberg Elin, Havulinna Aki S, Ho Weang K, Hopewell Jemma C, Eriksson Niclas, Kleber Marcus E, Kristiansson Kati, Lundmark Per, Lyytikäinen Leo-Pekka, Rafelt Suzanne, Shungin Dmitry, Strawbridge Rona J, Thorleifsson Gudmar, Tikkanen Emmi, Van Zuydam Natalie, Voight Benjamin F, Waite Lindsay L, Zhang Weihua, Ziegler Andreas, Absher Devin, Altshuler David, Balmforth Anthony J, Barroso Inês, Braund Peter S, Burgdorf Christof, Claudi-Boehm Simone, Cox David, Dimitriou Maria, Do Ron, Doney Alex S F, Mokhtari NourEddine El, Eriksson Per, Fischer Krista, Fontanillas Pierre, Franco-Cereceda Anders, Gigante Bruna, Groop Leif, Gustafsson Stefan, Hager Jörg, Hallmans Göran, Han Bok-Ghee, Hunt Sarah E, Kang Hyun M, Illig Thomas, Kessler Thorsten, Knowles Joshua W, Kolovou Genovefa, Kuusisto Johanna, Langenberg Claudia, Langford Cordelia, Leander Karin, Lokki Marja-Liisa, Lundmark Anders, McCarthy Mark I, Meisinger Christa, Melander Olle, Mihailov Evelin, Maouche Seraya, Morris Andrew D, Müller-Nurasyid Martina, Nikus Kjell, Peden John F, Rayner N William, Rasheed Asif, Rosinger Silke, Rubin Diana, Rumpf Moritz P, Schäfer Arne, Sivananthan Mohan, Song Ci, Stewart Alexandre F R, Tan Sian-Tsung, Thorgeirsson Gudmundur, Schoot C Ellen van der, Wagner Peter J, Wells George A, Wild Philipp S, Yang Tsun-Po, Amouyel Philippe, Arveiler Dominique, Basart Hanneke, Boehnke Michael, Boerwinkle Eric, Brambilla Paolo, Cambien Francois, Cupples Adrienne L, de Faire Ulf, Dehghan Abbas, Diemert Patrick, Epstein Stephen E, Evans Alun, Ferrario Marco M, Ferrières Jean, Gauguier Dominique, Go Alan S, Goodall Alison H, Gudnason Villi, Hazen Stanley L, Holm Hilma, Iribarren Carlos, Jang Yangsoo, Kähönen Mika, Kee Frank, Kim Hyo-Soo, Klopp Norman, Koenig Wolfgang, Kratzer Wolfgang, Kuulasmaa Kari, Laakso Markku, Laaksonen Reijo, Lee Ji-Young, Lind Lars, Ouwehand Willem H, Parish Sarah, Park Jeong E, Pedersen Nancy L, Peters Annette, Quertermous Thomas, Rader Daniel J, Salomaa Veikko, Schadt Eric, Shah Svati H, Sinisalo Juha, Stark Klaus, Stefansson Kari, Trégouët David-Alexandre, Virtamo Jarmo, Wallentin Lars, Wareham Nicholas, Zimmermann Martina E, Nieminen Markku S, Hengstenberg Christian, Sandhu Manjinder S, Pastinen Tomi, Syvänen Ann-Christine, Hovingh G Kees, Dedoussis George, Franks Paul W, Lehtimäki Terho, Metspalu Andres, Zalloua Pierre A, Siegbahn Agneta, Schreiber Stefan, Ripatti Samuli, Blankenberg Stefan S, Perola Markus, Clarke Robert, Boehm Bernhard O, O'Donnell Christopher, Reilly Muredach P, März Winfried, Collins Rory, Kathiresan Sekar, Hamsten Anders, Kooner Jaspal S, Thorsteinsdottir Unnur, Danesh John, Palmer Colin N A, Roberts Robert, Watkins Hugh, Schunkert Heribert, Samani Nilesh J. Large-scale association analysis identifies new risk loci for coronary artery disease. Nature Genetics. 2012;45(1):25–33. doi: 10.1038/ng.2480.
    1. Cordell HJ. Detecting gene-gene interactions that underlie human diseases. Nat Rev Genet. 2009;10:392–404. doi: 10.1038/nrg2579.
    1. Crutchley DJ, McPhee GV, Terris MF, Canossa-Terris MA. Levels of three hemostatic factors in relation to serum lipids. Monocyte procoagulant activity, tissue plasminogen activator, and type-1 plasminogen activator inhibitor. Arteriosclerosis. 1989;9:934–939. doi: 10.1161/atv81.9.6.2511826.
    1. De R, Verma SS, Drenos F, Holzinger ER, Holmes MV, Hall MA, Crosslin DR, Carrell DS, Hakonarson H, Jarvik G, Larson E, Pacheco JA, Rasmussen-Torvik LJ, Moore CB, Asselbergs FW, Moore JH, Ritchie MD, Keating BJ, Gilbert-Diamond D. Identifying gene-gene interactions that are highly associated with Body Mass Index using Quantitative Multifactor Dimensionality Reduction (QMDR) BioData Min. 2015;8:41. doi: 10.1186/s13040-015-0074-0.
    1. Diener HC, Eikelboom J, Granger CB, Hacke W. The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War? Int J Stroke. 2012;7:139–141. doi: 10.1111/j.1747-4949.2011.00739.x.
    1. Ellinghaus D, Ellinghaus E, Nair RP, Stuart PE, Esko T, Metspalu A, Debrus S, Raelson JV, Tejasvi T, Belouchi M, West SL, Barker JN, Koks S, Kingo K, Balschun T, Palmieri O, Annese V, Gieger C, Wichmann HE, Kabesch M, Trembath RC, Mathew CG, Abecasis GR, Weidinger S, Nikolaus S, Schreiber S, Elder JT, Weichenthal M, Nothnagel M, Franke A. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet. 2012;90:636–647. doi: 10.1016/j.ajhg.2012.02.020.
    1. Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 Factorial Mendelian Randomization Study. J Am Coll Cardiol. 2015;65:1552–1561. doi: 10.1016/j.jacc.2015.02.020.
    1. Fordyce CB, Roe MT, Ahmad T, Libby P, Borer JS, Hiatt WR, Bristow MR, Packer M, Wasserman SM, Braunstein N, Pitt B, DeMets DL, Cooper-Arnold K, Armstrong PW, Berkowitz SD, Scott R, Prats J, Galis ZS, Stockbridge N, Peterson ED, Califf RM. Cardiovascular drug development: is it dead or just hibernating? J Am Coll Cardiol. 2015;65:1567–1582. doi: 10.1016/j.jacc.2015.03.016.
    1. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR, Jr, Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre DE, Ogawa A, O’Neill KA, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1) Proc Natl Acad Sci USA. 2005;102:8132–8137. doi: 10.1073/pnas.0500269102.
    1. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012;40:D1100–D1107. doi: 10.1093/nar/gkr777.
    1. Willer Cristen J, Schmidt Ellen M, Sengupta Sebanti, Peloso Gina M, Gustafsson Stefan, Kanoni Stavroula, Ganna Andrea, Chen Jin, Buchkovich Martin L, Mora Samia, Beckmann Jacques S, Bragg-Gresham Jennifer L, Chang Hsing-Yi, Demirkan Ayşe, Den Hertog Heleen M, Do Ron, Donnelly Louise A, Ehret Georg B, Esko Tõnu, Feitosa Mary F, Ferreira Teresa, Fischer Krista, Fontanillas Pierre, Fraser Ross M, Freitag Daniel F, Gurdasani Deepti, Heikkilä Kauko, Hyppönen Elina, Isaacs Aaron, Jackson Anne U, Johansson Åsa, Johnson Toby, Kaakinen Marika, Kettunen Johannes, Kleber Marcus E, Li Xiaohui, Luan Jian'an, Lyytikäinen Leo-Pekka, Magnusson Patrik K E, Mangino Massimo, Mihailov Evelin, Montasser May E, Müller-Nurasyid Martina, Nolte Ilja M, O'Connell Jeffrey R, Palmer Cameron D, Perola Markus, Petersen Ann-Kristin, Sanna Serena, Saxena Richa, Service Susan K, Shah Sonia, Shungin Dmitry, Sidore Carlo, Song Ci, Strawbridge Rona J, Surakka Ida, Tanaka Toshiko, Teslovich Tanya M, Thorleifsson Gudmar, Van den Herik Evita G, Voight Benjamin F, Volcik Kelly A, Waite Lindsay L, Wong Andrew, Wu Ying, Zhang Weihua, Absher Devin, Asiki Gershim, Barroso Inês, Been Latonya F, Bolton Jennifer L, Bonnycastle Lori L, Brambilla Paolo, Burnett Mary S, Cesana Giancarlo, Dimitriou Maria, Doney Alex S F, Döring Angela, Elliott Paul, Epstein Stephen E, Eyjolfsson Gudmundur Ingi, Gigante Bruna, Goodarzi Mark O, Grallert Harald, Gravito Martha L, Groves Christopher J, Hallmans Göran, Hartikainen Anna-Liisa, Hayward Caroline, Hernandez Dena, Hicks Andrew A, Holm Hilma, Hung Yi-Jen, Illig Thomas, Jones Michelle R, Kaleebu Pontiano, Kastelein John J P, Khaw Kay-Tee, Kim Eric, Klopp Norman, Komulainen Pirjo, Kumari Meena, Langenberg Claudia, Lehtimäki Terho, Lin Shih-Yi, Lindström Jaana, Loos Ruth J F, Mach François, McArdle Wendy L, Meisinger Christa, Mitchell Braxton D, Müller Gabrielle, Nagaraja Ramaiah, Narisu Narisu, Nieminen Tuomo V M, Nsubuga Rebecca N, Olafsson Isleifur, Ong Ken K, Palotie Aarno, Papamarkou Theodore, Pomilla Cristina, Pouta Anneli, Rader Daniel J, Reilly Muredach P, Ridker Paul M, Rivadeneira Fernando, Rudan Igor, Ruokonen Aimo, Samani Nilesh, Scharnagl Hubert, Seeley Janet, Silander Kaisa, Stancáková Alena, Stirrups Kathleen, Swift Amy J, Tiret Laurence, Uitterlinden Andre G, van Pelt L Joost, Vedantam Sailaja, Wainwright Nicholas, Wijmenga Cisca, Wild Sarah H, Willemsen Gonneke, Wilsgaard Tom, Wilson James F, Young Elizabeth H, Zhao Jing Hua, Adair Linda S, Arveiler Dominique, Assimes Themistocles L, Bandinelli Stefania, Bennett Franklyn, Bochud Murielle, Boehm Bernhard O, Boomsma Dorret I, Borecki Ingrid B, Bornstein Stefan R, Bovet Pascal, Burnier Michel, Campbell Harry, Chakravarti Aravinda, Chambers John C, Chen Yii-Der Ida, Collins Francis S, Cooper Richard S, Danesh John, Dedoussis George, de Faire Ulf, Feranil Alan B, Ferrières Jean, Ferrucci Luigi, Freimer Nelson B, Gieger Christian, Groop Leif C, Gudnason Vilmundur, Gyllensten Ulf, Hamsten Anders, Harris Tamara B, Hingorani Aroon, Hirschhorn Joel N, Hofman Albert, Hovingh G Kees, Hsiung Chao Agnes, Humphries Steve E, Hunt Steven C, Hveem Kristian, Iribarren Carlos, Järvelin Marjo-Riitta, Jula Antti, Kähönen Mika, Kaprio Jaakko, Kesäniemi Antero, Kivimaki Mika, Kooner Jaspal S, Koudstaal Peter J, Krauss Ronald M, Kuh Diana, Kuusisto Johanna, Kyvik Kirsten O, Laakso Markku, Lakka Timo A, Lind Lars, Lindgren Cecilia M, Martin Nicholas G, März Winfried, McCarthy Mark I, McKenzie Colin A, Meneton Pierre, Metspalu Andres, Moilanen Leena, Morris Andrew D, Munroe Patricia B, Njølstad Inger, Pedersen Nancy L, Power Chris, Pramstaller Peter P, Price Jackie F, Psaty Bruce M, Quertermous Thomas, Rauramaa Rainer, Saleheen Danish, Salomaa Veikko, Sanghera Dharambir K, Saramies Jouko, Schwarz Peter E H, Sheu Wayne H-H, Shuldiner Alan R, Siegbahn Agneta, Spector Tim D, Stefansson Kari, Strachan David P, Tayo Bamidele O, Tremoli Elena, Tuomilehto Jaakko, Uusitupa Matti, van Duijn Cornelia M, Vollenweider Peter, Wallentin Lars, Wareham Nicholas J, Whitfield John B, Wolffenbuttel Bruce H R, Ordovas Jose M, Boerwinkle Eric, Palmer Colin N A, Thorsteinsdottir Unnur, Chasman Daniel I, Rotter Jerome I, Franks Paul W, Ripatti Samuli, Cupples L Adrienne, Sandhu Manjinder S, Rich Stephen S, Boehnke Michael, Deloukas Panos, Kathiresan Sekar, Mohlke Karen L, Ingelsson Erik, Abecasis Gonçalo R. Discovery and refinement of loci associated with lipid levels. Nature Genetics. 2013;45(11):1274–1283. doi: 10.1038/ng.2797.
    1. Gutstein DE, Krishna R, Johns D, Surks HK, Dansky HM, Shah S, Mitchel YB, Arena J, Wagner JA. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction. Clin Pharmacol Ther. 2012;91:109–122. doi: 10.1038/clpt.2011.271.
    1. Hewing B, Fisher EA. Rationale for cholesteryl ester transfer protein inhibition. Curr Opin Lipidol. 2012;23:372–376. doi: 10.1097/MOL.0b013e328353ef1d.
    1. Holmes MV, Simon T, Exeter HJ, Folkersen L, Asselbergs FW, Guardiola M, Cooper JA, Palmen J, Hubacek JA, Carruthers KF, Horne BD, Brunisholz KD, Mega JL, van Iperen EP, Li M, Leusink M, Trompet S, Verschuren JJ, Hovingh GK, Dehghan A, Nelson CP, Kotti S, Danchin N, Scholz M, Haase CL, Rothenbacher D, Swerdlow DI, Kuchenbaecker KB, Staines-Urias E, Goel A, van’t Hooft F, Gertow K, de Faire U, Panayiotou AG, Tremoli E, Baldassarre D, Veglia F, Holdt LM, Beutner F, Gansevoort RT, Navis GJ, Mateo Leach I, Breitling LP, Brenner H, Thiery J, Dallmeier D, Franco-Cereceda A, Boer JM, Stephens JW, Hofker MH, Tedgui A, Hofman A, Uitterlinden AG, Adamkova V, Pitha J, Onland-Moret NC, Cramer MJ, Nathoe HM, Spiering W, Klungel OH, Kumari M, Whincup PH, Morrow DA, Braund PS, Hall AS, Olsson AG, Doevendans PA, Trip MD, Tobin MD, Hamsten A, Watkins H, Koenig W, Nicolaides AN, Teupser D, Day IN, Carlquist JF, Gaunt TR, Ford I, Sattar N, Tsimikas S, Schwartz GG, Lawlor DA, Morris RW, Sandhu MS, Poledne R, Maitland-van der Zee AH, Khaw KT, Keating BJ, van der Harst P, Price JF, Mehta SR, Yusuf S, Witteman JC, Franco OH, Jukema JW, de Knijff P, Tybjaerg-Hansen A, Rader DJ, Farrall M, Samani NJ, et al. Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol. 2013;62:1966–1976. doi: 10.1016/j.jacc.2013.06.044.
    1. Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, Prieto-Merino D, Dehghan A, Trompet S, Wong A, Cavadino A, Drogan D, Padmanabhan S, Li S, Yesupriya A, Leusink M, Sundstrom J, Hubacek JA, Pikhart H, Swerdlow DI, Panayiotou AG, Borinskaya SA, Finan C, Shah S, Kuchenbaecker KB, Shah T, Engmann J, Folkersen L, Eriksson P, Ricceri F, Melander O, Sacerdote C, Gamble DM, Rayaprolu S, Ross OA, McLachlan S, Vikhireva O, Sluijs I, Scott RA, Adamkova V, Flicker L, Bockxmeer FM, Power C, Marques-Vidal P, Meade T, Marmot MG, Ferro JM, Paulos-Pinheiro S, Humphries SE, Talmud PJ, Mateo Leach I, Verweij N, Linneberg A, Skaaby T, Doevendans PA, Cramer MJ, van der Harst P, Klungel OH, Dowling NF, Dominiczak AF, Kumari M, Nicolaides AN, Weikert C, Boeing H, Ebrahim S, Gaunt TR, Price JF, Lannfelt L, Peasey A, Kubinova R, Pajak A, Malyutina S, Voevoda MI, Tamosiunas A, Maitland-van der Zee AH, Norman PE, Hankey GJ, Bergmann MM, Hofman A, Franco OH, Cooper J, Palmen J, Spiering W, de Jong PA, Kuh D, Hardy R, Uitterlinden AG, Ikram MA, Ford I, Hypponen E, Almeida OP, Wareham NJ, Khaw KT, Hamsten A, Husemoen LL, Tjonneland A, Tolstrup JS, Rimm E, Beulens JW, Verschuren WM, et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ. 2014;349:g4164. doi: 10.1136/bmj.g4164.
    1. Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, Dale CE, Padmanabhan S, Finan C, Swerdlow DI, Tragante V, van Iperen EP, Sivapalaratnam S, Shah S, Elbers CC, Shah T, Engmann J, Giambartolomei C, White J, Zabaneh D, Sofat R, McLachlan S, on behalf of the Uc. Doevendans PA, Balmforth AJ, Hall AS, North KE, Almoguera B, Hoogeveen RC, Cushman M, Fornage M, Patel SR, Redline S, Siscovick DS, Tsai MY, Karczewski KJ, Hofker MH, Verschuren WM, Bots ML, van der Schouw YT, Melander O, Dominiczak AF, Morris R, Ben-Shlomo Y, Price J, Kumari M, Baumert J, Peters A, Thorand B, Koenig W, Gaunt TR, Humphries SE, Clarke R, Watkins H, Farrall M, Wilson JG, Rich SS, de Bakker PI, Lange LA, Davey Smith G, Reiner AP, Talmud PJ, Kivimaki M, Lawlor DA, Dudbridge F, Samani NJ, Keating BJ, Hingorani AD, Casas JP. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2015;36:539–550. doi: 10.1093/eurheartj/eht571.
    1. Jarcho John A., Keaney John F. Proof That Lower Is Better — LDL Cholesterol and IMPROVE-IT. New England Journal of Medicine. 2015;372(25):2448–2450. doi: 10.1056/NEJMe1507041.
    1. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E, Investigators E. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431–1443. doi: 10.1056/NEJMoa0800742.
    1. Kathiresan S. Developing medicines that mimic the natural successes of the human genome: lessons from NPC1L1, HMGCR, PCSK9, APOC3, and CETP. J Am Coll Cardiol. 2015;65:1562–1566. doi: 10.1016/j.jacc.2015.02.049.
    1. Kaur N, Pandey A, Negi H, Shafiq N, Reddy S, Kaur H, Chadha N, Malhotra S. Effect of HDL-raising drugs on cardiovascular outcomes: a systematic review and meta-regression. PLoS One. 2014;9:e94585. doi: 10.1371/journal.pone.0094585.
    1. Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ. 2014;349:g4379. doi: 10.1136/bmj.g4379.
    1. Keidan B, Hsia J, Katz R. Plasma lipids and antidiabetic agents: a brief overview. Br J Diabetes Vasc Dis. 2002;2:40–43. doi: 10.1177/14746514020020011801.
    1. Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, Civeira F, Somaratne R, Nelson P, Liu T, Scott R, Wasserman SM, Sabatine MS, Investigators O. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014;129:234–243. doi: 10.1161/CIRCULATIONAHA.113.007012.
    1. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13:221–228. doi: 10.1111/j.1463-1326.2010.01349.x.
    1. Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, Maciejewski A, Arndt D, Wilson M, Neveu V, Tang A, Gabriel G, Ly C, Adamjee S, Dame ZT, Han B, Zhou Y, Wishart DS. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014;42:D1091–D1097. doi: 10.1093/nar/gkt1068.
    1. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27:1133–1163. doi: 10.1002/sim.3034.
    1. Lilly (2015) Lilly to discontinue development of evacetrapib for high-risk atherosclerotic cardiovascular disease. . Accessed 5 Nov 2015
    1. Lin DY, Zeng D. Meta-analysis of genome-wide association studies: no efficiency gain in using individual participant data. Genet Epidemiol. 2010;34:60–66.
    1. Lowe GD, Danesh J, Lewington S, Walker M, Lennon L, Thomson A, Rumley A, Whincup PH. Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. Eur Heart J. 2004;25:252–259. doi: 10.1016/j.ehj.2003.11.004.
    1. Major LF, Goyer PF. Effects of disulfiram and pyridoxine on serum cholesterol. Ann Intern Med. 1978;88:53–56. doi: 10.7326/0003-4819-88-1-53.
    1. McGeachie MJ, Clemmer GL, Lasky-Su J, Dahlin A, Raby BA, Weiss ST. Joint GWAS Analysis: comparing similar GWAS at different genomic resolutions identifies novel pathway associations with six complex diseases. Genomics Data. 2014;2:202–211. doi: 10.1016/j.gdata.2014.04.004.
    1. McPherson R, Hegele RA. Ezetimibe: rescued by randomization (clinical and mendelian) Arterioscler Thromb Vasc Biol. 2015;35:e13–e15. doi: 10.1161/ATVBAHA.114.305012.
    1. Miller NE. CETP inhibitors and cardiovascular disease: time to think again. F1000Res. 2014;3:124. doi: 10.12688/f1000research.4396.1.
    1. Mohammadpour AH, Akhlaghi F. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective. Clin Pharmacokinet. 2013;52:615–626. doi: 10.1007/s40262-013-0071-8.
    1. Myocardial Infarction Genetics Consortium I. Stitziel NO, Won HH, Morrison AC, Peloso GM, Do R, Lange LA, Fontanillas P, Gupta N, Duga S, Goel A, Farrall M, Saleheen D, Ferrario P, Konig I, Asselta R, Merlini PA, Marziliano N, Notarangelo MF, Schick U, Auer P, Assimes TL, Reilly M, Wilensky R, Rader DJ, Hovingh GK, Meitinger T, Kessler T, Kastrati A, Laugwitz KL, Siscovick D, Rotter JI, Hazen SL, Tracy R, Cresci S, Spertus J, Jackson R, Schwartz SM, Natarajan P, Crosby J, Muzny D, Ballantyne C, Rich SS, O’Donnell CJ, Abecasis G, Sunyaev S, Nickerson DA, Buring JE, Ridker PM, Chasman DI, Austin E, Ye Z, Kullo IJ, Weeke PE, Shaffer CM, Bastarache LA, Denny JC, Roden DM, Palmer C, Deloukas P, Lin DY, Tang ZZ, Erdmann J, Schunkert H, Danesh J, Marrugat J, Elosua R, Ardissino D, McPherson R, Watkins H, Reiner AP, Wilson JG, Altshuler D, Gibbs RA, Lander ES, Boerwinkle E, Gabriel S, Kathiresan S. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014;371:2072–2082. doi: 10.1056/NEJMoa1405386.
    1. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, Floratos A, Sham PC, Li MJ, Wang J, Cardon LR, Whittaker JC, Sanseau P. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47:856–860. doi: 10.1038/ng.3314.
    1. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, Southan C, Spedding M, Yu W, Harmar AJ, Nc I. The IUPHAR/BPS guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res. 2014;42:D1098–D1106. doi: 10.1093/nar/gkt1143.
    1. Pentikainen PJ, Voutilainen E, Aro A, Uusitupa M, Penttila I, Vapaatalo H. Cholesterol lowering effect of metformin in combined hyperlipidemia: placebo controlled double blind trial. Ann Med. 1990;22:307–312. doi: 10.3109/07853899009147912.
    1. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556–2564. doi: 10.1001/jama.2011.860.
    1. Rask-Andersen M, Masuram S, Schioth HB. The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu Rev Pharmacol Toxicol. 2014;54:9–26. doi: 10.1146/annurev-pharmtox-011613-135943.
    1. Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care. 1998;21:701–705. doi: 10.2337/diacare.21.5.701.
    1. Sakkinen PA, Cushman M, Psaty BM, Rodriguez B, Boineau R, Kuller LH, Tracy RP. Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women. Arterioscler Thromb Vasc Biol. 1999;19:499–504. doi: 10.1161/01.ATV.19.3.499.
    1. Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med. 2008;121(149–157):e2.
    1. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–742. doi: 10.1016/S0140-6736(09)61965-6.
    1. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS, Dal OI. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–2099. doi: 10.1056/NEJMoa1206797.
    1. Sofat R, Hingorani AD, Smeeth L, Humphries SE, Talmud PJ, Cooper J, Shah T, Sandhu MS, Ricketts SL, Boekholdt SM, Wareham N, Khaw KT, Kumari M, Kivimaki M, Marmot M, Asselbergs FW, van der Harst P, Dullaart RP, Navis G, van Veldhuisen DJ, Van Gilst WH, Thompson JF, McCaskie P, Palmer LJ, Arca M, Quagliarini F, Gaudio C, Cambien F, Nicaud V, Poirer O, Gudnason V, Isaacs A, Witteman JC, van Duijn CM, Pencina M, Vasan RS, D’Agostino RB, Sr, Ordovas J, Li TY, Kakko S, Kauma H, Savolainen MJ, Kesaniemi YA, Sandhofer A, Paulweber B, Sorli JV, Goto A, Yokoyama S, Okumura K, Horne BD, Packard C, Freeman D, Ford I, Sattar N, McCormack V, Lawlor DA, Ebrahim S, Smith GD, Kastelein JJ, Deanfield J, Casas JP. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation. 2010;121:52–62. doi: 10.1161/CIRCULATIONAHA.109.865444.
    1. Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366:1108–1118. doi: 10.1056/NEJMoa1105803.
    1. Stein EA, Giugliano RP, Koren MJ, Raal FJ, Roth EM, Weiss R, Sullivan D, Wasserman SM, Somaratne R, Kim JB, Yang J, Liu T, Albizem M, Scott R, Sabatine MS, Investigators P. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J. 2014;35:2249–2259. doi: 10.1093/eurheartj/ehu085.
    1. Swerdlow Daniel I, Preiss David, Kuchenbaecker Karoline B, Holmes Michael V, Engmann Jorgen E L, Shah Tina, Sofat Reecha, Stender Stefan, Johnson Paul C D, Scott Robert A, Leusink Maarten, Verweij Niek, Sharp Stephen J, Guo Yiran, Giambartolomei Claudia, Chung Christina, Peasey Anne, Amuzu Antoinette, Li KaWah, Palmen Jutta, Howard Philip, Cooper Jackie A, Drenos Fotios, Li Yun R, Lowe Gordon, Gallacher John, Stewart Marlene C W, Tzoulaki Ioanna, Buxbaum Sarah G, van der A Daphne L, Forouhi Nita G, Onland-Moret N Charlotte, van der Schouw Yvonne T, Schnabel Renate B, Hubacek Jaroslav A, Kubinova Ruzena, Baceviciene Migle, Tamosiunas Abdonas, Pajak Andrzej, Topor-Madry Romanvan, Stepaniak Urszula, Malyutina Sofia, Baldassarre Damiano, Sennblad Bengt, Tremoli Elena, de Faire Ulf, Veglia Fabrizio, Ford Ian, Jukema J Wouter, Westendorp Rudi G J, de Borst Gert Jan, de Jong Pim A, Algra Ale, Spiering Wilko, der Zee Anke H Maitland-van, Klungel Olaf H, de Boer Anthonius, Doevendans Pieter A, Eaton Charles B, Robinson Jennifer G, Duggan David, Kjekshus John, Downs John R, Gotto Antonio M, Keech Anthony C, Marchioli Roberto, Tognoni Gianni, Sever Peter S, Poulter Neil R, Waters David D, Pedersen Terje R, Amarenco Pierre, Nakamura Haruo, McMurray John J V, Lewsey James D, Chasman Daniel I, Ridker Paul M, Maggioni Aldo P, Tavazzi Luigi, Ray Kausik K, Seshasai Sreenivasa Rao Kondapally, Manson JoAnn E, Price Jackie F, Whincup Peter H, Morris Richard W, Lawlor Debbie A, Smith George Davey, Ben-Shlomo Yoav, Schreiner Pamela J, Fornage Myriam, Siscovick David S, Cushman Mary, Kumari Meena, Wareham Nick J, Verschuren W M Monique, Redline Susan, Patel Sanjay R, Whittaker John C, Hamsten Anders, Delaney Joseph A, Dale Caroline, Gaunt Tom R, Wong Andrew, Kuh Diana, Hardy Rebecca, Kathiresan Sekar, Castillo Berta A, van der Harst Pim, Brunner Eric J, Tybjaerg-Hansen Anne, Marmot Michael G, Krauss Ronald M, Tsai Michael, Coresh Josef, Hoogeveen Ronald C, Psaty Bruce M, Lange Leslie A, Hakonarson Hakon, Dudbridge Frank, Humphries Steve E, Talmud Philippa J, Kivimäki Mika, Timpson Nicholas J, Langenberg Claudia, Asselbergs Folkert W, Voevoda Mikhail, Bobak Martin, Pikhart Hynek, Wilson James G, Reiner Alex P, Keating Brendan J, Hingorani Aroon D, Sattar Naveed. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. The Lancet. 2015;385(9965):351–361. doi: 10.1016/S0140-6736(14)61183-1.
    1. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361:2113–2122. doi: 10.1056/NEJMoa0907569.
    1. Thomas DC, Lawlor DA, Thompson JR, et al. Re: estimation of bias in nongenetic observational studies using “Mendelian triangulation” by Bautista et al. Ann Epidemiol. 2007;17:511–513. doi: 10.1016/j.annepidem.2006.12.005.
    1. Thorn CF, Klein TE, Altman RB. Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics. 2010;11:501–505. doi: 10.2217/pgs.10.15.
    1. Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med. 2004;256:1–14. doi: 10.1111/j.1365-2796.2004.01328.x.
    1. Zhernakova A, Stahl EA, Trynka G, Raychaudhuri S, Festen EA, Franke L, Westra HJ, Fehrmann RS, Kurreeman FA, Thomson B, Gupta N, Romanos J, McManus R, Ryan AW, Turner G, Brouwer E, Posthumus MD, Remmers EF, Tucci F, Toes R, Grandone E, Mazzilli MC, Rybak A, Cukrowska B, Coenen MJ, Radstake TR, van Riel PL, Li Y, de Bakker PI, Gregersen PK, Worthington J, Siminovitch KA, Klareskog L, Huizinga TW, Wijmenga C, Plenge RM. Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet. 2011;7:e1002004. doi: 10.1371/journal.pgen.1002004.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit